|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.
|
29905907 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<b>Expert opinion</b>: Multiparametric magnetic resonance imaging (mpMRI) and subsequent-targeted biopsy have improved the diagnostic accuracy of PCa detection in men with an elevated or rising serum PSA.
|
31277551 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The introduction of Prostate Specific Antigen (PSA) screening has caused a stage shift in diagnosis of prostate cancer and an increasing number of patients receiving early diagnosis.
|
30324348 |
2019 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Prostate cancer (PCa) testing is currently based on measurement of serum prostate‑specific antigen levels and digital rectal examination, which are limited by a low predictive value and the adverse effects associated with overdiagnosis and overtreatment.
|
30483762 |
2019 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recently, the rs61752561 SNP (Asp84Asn substitution) in exon 3 of the kallikrein-related peptidase 3 (<i>KLK3</i>) gene encoding prostate-specific antigen (PSA) was reported to be strongly associated with PCa risk (<i>P</i> = 2.3 × 10<sup>-8</sup>).
|
30538125 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
A 71-year-old man with history of prostate cancer is evaluated for rising prostate-specific antigen.
|
30371597 |
2019 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In human prostate cancer cell line, LNCaP, PRE could reduce the cell growth, down-regulate the expression of AR and suppress prostate-specific antigen (PSA) secretion.
|
31489669 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We find no significant association between the risk of ISUP 1 prostate cancer and PSA and age at diagnosis indicating that PSA contribution from ISUP 1 prostate cancer is closer to that of benign prostate tissue than to that of ISUP ≥ 2 prostate cancer.
|
31194822 |
2019 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The sensor responds to different levels of PSA in serum, correlating well with chemiluminescence ELISA used in hospitals even with higher potential to discriminate clinically meaningful prostate cancer.
|
30640124 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Prostate specific antigen (PSA) has been widely used as the unique serum biomarker for the diagnosis and/ or pre-diagnosis of prostate cancer (PCa).
|
28730787 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
None of the screening/biopsy measures (testing frequency, mean interval, PSA velocity, highest pre-diagnostic PSA or prior negative biopsy) were associated with uptake of AS among men with low risk PCa.
|
31383015 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
With the availability of ultra-sensitive PSA assays, early biochemical relapse (eBCR) of prostate cancer is increasingly being detected at values much lower than the conventional threshold of 0.2 ng/ml.
|
30617554 |
2019 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In addition, the PSA levels were correlated with the expression of DRD1 in BPH cases and DRD1, DRD4, DRD5, and IL6 in PCa cases.
|
31288722 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
By utilizing this additional data to determine MRI-defined PSA density, we find that risk discrimination for clinically significant PCa on biopsy can be significantly improved.
|
30580005 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Because of significant stability of the prepared Ab<sub>1</sub>-AuNPs and excellent selectivity to the PSA antigen, this simple and sensitive sensing system is proposed to be potentially effective in the fast and real-time analysis of clinical samples from prostate cancer patients.
|
31174151 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We compared the factors including age, postoperative maximal flow rate (MFR; mL/s), postoperative prostate-specific antigen (PSA) (ng/mL), preoperative MFR (mL/s), preoperative PSA (ng/mL), prostate cancer (%), operative time (min), preoperative residual urine (mL), postoperative residual urine (mL), urinary incontinence (day 1; %), urinary incontinence (1 month; %), urinary incontinence (3 months; %), urethral catheter indwelling period (days), morcellation time (min), enucleation time (min), intraoperative complications (%), postoperative complications (%), prostate volume (mL), enucleated weight (g), and hospitalization period (days).
|
31801152 |
2019 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Specifically, soy isoflavones have been determined to downregulate the prostate cancer cell androgen receptors, reverse the epithelial to mesenchymal transition of these cells, decrease the expressions of prostate-specific antigen, matrix metalloproteinase and serine proteinase, and reduce the superficial membrane fluidity in prostate cancer cells.
|
30956643 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The United States Preventive Services Task Force (USPSTF) issued an updated recommendation statement on serum Prostate Specific Antigen (PSA)-based screening for PCa.
|
30855080 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
In a heavily pretreated population of men with mCRPC, pembrolizumab was associated with a ≥50% PSA decline in 17% (8/48) of men, including a dramatic ≥90% PSA response in 8% (4/48), two of whom harbored pathogenic LRP1b mutations suggesting that LRP1b mutations may enrich for PD-1 inhibitor responsiveness in prostate cancer.
|
31270961 |
2019 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
SigPCa probabilities were calculated with the two PSA measures using ERSPC3/4+digital rectal examination and PCPT v2+free PSA RCs.
|
31722940 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Men with Grade Group 1, prostate specific antigen 10 to 15 ng/ml and prostate specific antigen density less than 0.15 ng/ml/cm did not significantly differ in upgrading or adverse pathology findings compared to men with low risk prostate cancer.
|
30240688 |
2019 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Following years of controversy regarding screening for prostate cancer using prostate-specific antigen, evidence evolves towards a more restrained and preference-based use.
|
31194773 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening: A 21-year follow-up study.
|
31183899 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
A multiplex model incorporating all the above genes and clinical information (PSA, age) identified patients with GG ≥ 2 PC (AUC 0.815, p < 0.0001).
|
31779677 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We defined PSA screening in men aged 75 years or older without a history of prostate cancer as low value, per established definitions in Medicare.
|
31276198 |
2019 |